|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes显示文摘 | Yi-Ping Rao Elaine J. Studer R.Todd Stravitz Seema Gupta Liang Qiao Paul Dent Phillip B. Hylemon | 2002 | Hepatology2002，，2： | 2 |
| 2 | Regulation of mda-7 gene expression during human melanoma differentiation 显示文摘 | Madireddi T P Dent Paul Fisher | 2000 | Oncogene2000，19，10： | 1 |
| 3 | Characterisation of salt films on dissolving metal surfaces in artificial corrosion pits via in situ synchrotron X-ray diffraction显示文摘 | Trevor Rayment Alison J. Davenport Andrew J. Dent Jean-Philippe Tinnes Richard J.K. Wiltshire Christopher Martin Graham Clark Paul Quinn J. Fred W. Mosselmans | 2008 | Electrochemistry Communications2008，，6： | 1 |
| 4 | Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes显示文摘 | Liang Qiao Adly Yacoub Elaine Studer Seema Gupta Xin Yan Pei Steven Grant Philip B. Hylemon Paul Dent | 2002 | Hepatology2002，，4： | 1 |
| 5 | Thelper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6显示文摘 | Dent A L Hu L J Paul W E | 1998 | Proc Nail Acad Sci U S A1998，95，13： | 1 |
| 6 | mda-7 /IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine显示文摘 | Pankaj Gupta Zao-zhong Su Irina V. Lebedeva Devanand Sarkar Moira Sauane Luni Emdad Michael A. Bachelor Steven Grant David T. Curiel Paul Dent Paul B. Fisher | 2006 | Pharmacology and Therapeutics2006，，3： | 1 |
| 7 | BCL-6-defi- cient mice reveal an IL-4-independent, STAT6-de pendent pathway that controls susceptibility to in- fection by Leishmania major显示文摘 | Dent AL Doherty TM Paul WE | 1999 | J Immunol1999，163，4： | 1 |
| 8 | Distal small bowel motility and lipid absorption in patients following abdominal aortic aneurysm repair surgery显示文摘瞄准:在跟随选任的腹的主动脉瘤(AAA ) 修理外科的病人调查远侧的小肠活动性和类脂化合物吸收。方法:九个病人(年老的 35-78 年;身体团索引(BMI ) 范围:23-36 kg/m (2 )) 为 AAA 修理,和七个健康控制题目外科以后(20-50 年;BMI 变化:21-29 kg/m (2 )) 被学习。连续的远侧的小肠测压法为多达 72 h 被执行,在 fasting 并且肠内的的喂(Nutrison ) 的时期期间。记录为频率,起源,一些移植,和小肠的爆炸活动的方向被分析。类脂化合物吸收在病人的一个子集在第一天和第三个天柱子手术被估计用(13 ) C-triolein-breath 测试,并且与健康控制相比。题目收到了 50 mL 液体的 20-min 十二指肠内注入喂与 200 混合了 microL (13 ) C-triolein。结束吐气的呼吸样品为 6 h 被收集并且分析了为(13 ) 公司(2 ) 集中。结果:在近似、远侧的小肠的爆炸活动的频率比在健康题目在病人是更高的,在 fasting 和美联储条件(P<0.005 ) 下面。在病人,有反常地宣传的爆炸的一个更高的比例(71% 反常) ,它开始由 d 使正常化 3 (25% 反常) 外科以后。类脂化合物吸收数据为 d 上的七个病人是可得到的 d 上的 1 和四个病人 3 帖子外科。在病人, d 上的吸收 1 外科以后是健康控制的使遭到的一半(AUC (13 ) 公司(2 ) 1323+/-244 对 2646+/-365;P<0.05,分别地) ,并且被归结为五分之一个由 d 的健康控制的 3 (AUC (13 ) 公司(2 ) 470+/-832 对 2646+/-365;P<0.05,分别地) 。结论:近似、远侧的小肠的马达活动短暂地在主要外科以后立即在非常有病的病人被破坏,与远及回肠延长的反常活动性模式。这些马达骚乱可以贡献肠内的营养的损害吸收,特别当管腔内处理为有效消化是必要的时。 | Robert J Fraser Marc Ritz Addolorata C Di Matteo Rosalie Vozzo Monika Kwiatek Robert Foreman Brendan Stanley Jack Walsh Jim Burnett Paul Jury John Dent | 2006 | World Journal of Gastroenterology2006，12，4： | 1 |
| 9 | Deferred Taxes Forever-Professional Notes 显示文摘 | Defliese Philip L Paul Rosenfield William C Dent | 1983 | Journal of Ac- countancy1983，156，2： | 1 |
| 10 | Autophagy and the functional roles of Atg5 and beclin-1 in the anti-tumor effects of 3β androstene 17α diol neuro-steroid on malignant glioma cells显示文摘 | Martin R. Graf Wentao Jia Ross S. Johnson Paul Dent Clint Mitchell Roger M. Loria | 2009 | Journal of Steroid Biochemistry and Molecular Biology2009，，： | 1 |
| 11 | Targeting the Bcl-2 family for cancer therapy显示文摘 | Shibu Thomas Bridget A Quinn Swadesh K Das Rupesh Dash Luni Emdad Santanu Dasgupta Xiang-Yang Wang Paul Dent John C Reed Maurizio Pellecchia Devanand Sarkar Paul B Fisher | 2013 | Expert Opinion on Therapeutic Targets2013，，1： | 1 |
| 12 | Targeting the Bcl-2 family for cancer therapy显示文摘 | Shibu Thomas Bridget A Quinn Swadesh K Das Rupesh Dash Luni Emdad Santanu Dasgupta Xiang-Yang Wang Paul Dent John C Reed Maurizio Pellecchia Devanand Sarkar Paul B Fisher | 2013 | Expert Opinion on Therapeutic Targets2013，，1： | 1 |
| 13 | 不翻瓣方式前牙美学种植的风险与优点:病例报告显示文摘成功的美学前牙种植仍主要取决于能够保存或重建起来的软组织协调自然的程度。很多保存或增量软硬组织外形和体积的技术已经被描述.尤其在上颌前牙美学敏感区域。但是其可预期性不同。本文结合几个病例阐述可以提高临床预期性的一些临床方法。 | Stefan Paul PD Dr med dent 陈波(译) | 2009 | 中国口腔医学继续教育杂志2009，，3： | 0 |
| 14 | Kinase inhibitors:look beyond the label on the bottle显示文摘The majority of scientists working in the field of cancer experimental therapeutics recognize that many drugs that claim to be“specific”for one target enzyme in fact regulate to varying degrees the activities of other additional protein targets.Some of these targets are known and are recognized as being an essential component of a drug’s biology.However,many other targets fall into the category of“unknown unknowns”.Thus,the collective therapeutic outcome for almost all clinically relevant drugs is reliant on both the claimed primary and secondary“on”targets as well as some of the unexpected unknown“off”targets.This review discusses the biology of several FDA approved cancer therapeutic drugs whose initial reported targets only represented the tip-of-the-iceberg in terms of how each agent acted as an anti-tumor drug.The review also discusses a putative thorough pre-visualization methodology for drug-based research,prior to executing any wet work.These approaches should be performed in an agnostic fashion and be based in part on the clinically safe drug’s C max and its area under the curve in a patient.Based on tumor heterogeneity,considerations of how to approach developmental therapeutics in the age of“personalized medicine”are also discussed. | Paul Dent Andrew Poklepovic Laurence Booth John F.Hancock | 2019 | Cancer Drug Resistance2019，2，4： | 0 |
| 15 | Competing risks of death in younger and older postmenopausal breast cancer patients显示文摘AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramuscular injections monthly. Event-free survival was the primary endpoint of MA.14; at median 7.9 years, the tamoxifen+octreotide and tamoxifen arms had similar event-free survival(P = 0.62). Overall survival was a secondary endpoint, and the two trial arms also had similar overall survival(P = 0.86). We used the median 9.8 years follow-up to examine by intention-to-treat, the multivariate time-to-breast cancer-specific(Br Ca) and other cause(OC) mortality with log-normal survival analysis adjusted by treatment and stratification factors. We tested whether baseline factors including Insulin-like growth factor 1(IGF1), IGF binding protein-3, C-peptide, body mass index, and 25-OH vitamin D were associated with(1) all cause mortality, and if so; and(2) cause-specific mortality. We also fit step-wise forward cause-specific adjusted models.RESULTS: The analyses were performed on 329 patients allocated tamoxifen and 329 allocated tamoxifen+octreotide. The median age of MA.14 patients was 60.1 years: 447(82%) < 70 years and 120(18%) ≥ 70 years. There were 170 deaths: 106(62.3%) BrC a; 55(32.4%) OC, of which 24 were other malignancies, 31 other causes of death; 9(5.3%) patients with unknown cause of death were excluded from competing risk assessments. BrC a and OC deaths were not significantly different by treatment arm(P = 0.40): tamoxifen patients experienced 50 BrC a and 32 OC deaths, while tamoxifen + octreotide patients experienced 56 Br Ca and 23 OC deaths. Proportionately more deaths(P = 0.004) were from BrC a for patients< 70 years, where 70% of deaths were due to Br Ca, compared to 54% for those ≥ 70 years of age. The proportion of deaths from OC increased with increasing body mass index(BMI)(P = 0.02). Higher pathologic T and N were associated with more BrC a deaths(P < 0.0001 and 0.002, respectively). The cumulative hazard plot for Br Ca and OC mortality indicated the concurrent accrual of both types of death throughout followup, that is the existence of competing risks of mortality. MA.14 therapy did not impact mortality(P = 0.77). Three baseline patient and tumor characteristics were differentially associated with cause of death: older patients experienced more OC(P = 0.01) mortality; patients with T1 tumors and hormone receptor positive tumors had less BrC a mortality(respectively, P = 0.01, P = 0.06). Additionally, step-wise cause-specific models indicated that patients with node negative disease experienced less BrC a mortality(P = 0.002); there was weak evidence that, lower C-peptide(P = 0.08) was associated with less BrC a mortality, while higher BMI(P = 0.01) was associated with worse OC mortality.CONCLUSION: We demonstrate here a new paradigm of simultaneous testing of therapeutics directed at multiple diseases for which postmenopausal women are concurrently at risk. Octreotide LAR did not significantly impact breast cancer or other cause mortality, although different baseline factors influenced type of death. | Judy-Anne W Chapman Kathleen I Pritchard Paul E Goss James N Ingle Hyman B Muss Susan F Dent Ted A Vandenberg Brian Findlay Karen A Gelmon Carolyn F Wilson Lois E Shepherd Michael N Pollak | 2014 | World Journal of Clinical Oncology2014，5，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员